30/07/2026
Lipfendra (enlicitide) — the world’s first once-daily oral PCSK9 inhibitor — was FDA-approved on July 16, 2026. What does this mean for heart health in urban India? Read our quick breakdown: accessibility, adherence, and real-world impact for patients at risk. Read more: https://wix.to/6NnOYC1
On July 16, 2026, the U.S. FDA marked a significant milestone in cardiovascular medicine by approving Lipfendra (enlicitide). It is the world’s first once-daily oral PCSK9 inhibitor pill.